When Can We Rely on Real‐World Evidence to Evaluate New Medical Treatments?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

When Can We Rely on Real‐World Evidence to Evaluate New Medical Treatments?

Published:2021-05-19 Issue:1 Volume:111 Page:30-34
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Simon Gregory E.¹,Platt Richard²,Watanabe Jonathan H.³,Bindman Andrew B.⁴,John London Alex⁵,Horberg Michael⁶,Hernandez Adrian⁷,Califf Robert M.⁸

Affiliation:

1. Kaiser Permanente Washington Health Research Institute

2. Harvard Pilgrim Health Care Institute Harvard Medical School

3. School of Pharmacy and Pharmaceutical Sciences University of California Irvine

4. Kaiser Foundation Health Plan and Hospitals

5. Philosophy Department & Center for Ethics and Policy Carnegie Mellon University

6. Kaiser Permanente Mid‐Atlantic Permanente Research Institute Mid‐Atlantic Permanente Medical Group

7. Duke Clinical Research Institute

8. Verily Life Sciences and Google Health

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2253

Reference38 articles.

1. Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness

2. Real-World Evidence — What Is It and What Can It Tell Us?

3. The Imperative of Overcoming Barriers to the Conduct of Large, Simple Trials

4. How much do clinical trials cost?

5. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Determining the value of the abdominal core health quality collaborative to support regulatory decisions;Hernia;2024-04-29

2. Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea;Advances in Therapy;2024-04-15

3. Preliminary Attainability Assessment of Real-World Data for Answering Major Clinical Research Questions in Breast Cancer Brain Metastasis: Framework Development and Validation Study;Journal of Medical Internet Research;2023-03-23

4. Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United States;PharmacoEconomics - Open;2023-02-25

5. The evolving role of data & safety monitoring boards for real-world clinical trials;Journal of Clinical and Translational Science;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3